Abstract
Background and purpose The frequency of ischemic stroke in patients with COVID-19 varies in the current literature, and risk factors are unknown. We assessed the incidence, risk factors, and outcomes of acute ischemic stroke in hospitalized patients with COVID-19.
Methods We included patients with a laboratory confirmed SARS-CoV-2 infection admitted in 16 hospitals participating in the international CAPACITY-COVID registry between March 1st and August 1st, 2020. Patients were screened for the occurrence of acute ischemic stroke. We calculated the cumulative incidence of ischemic stroke and compared risk factors, cardiovascular complications, and in-hospital mortality in patients with and without ischemic stroke.
Results We included 2147 patients with COVID-19, of whom 586 (27.3%) needed treatment at an intensive care unit (ICU). Thirty-eight patients (1.8%) had an ischemic stroke. Patients with stroke were older, but did not differ in sex or cardiovascular risk factors. Median time between onset of COVID-19 symptoms and diagnosis of stroke was two weeks. The incidence of ischemic stroke was higher among patients who were treated at an ICU (16/586; 2.7% versus 22/1561; 1.4%; p=0.039). Pulmonary embolism was more common in patients with (8/38; 21.1%) than in those without stroke (160/2109; 7.6%; adjusted RR: 2.08; 95%CI:1.52-2.84). Twenty-seven patients with ischemic stroke (71.1%) died during admission or were functional dependent at discharge and in-hospital mortality. Patients with ischemic stroke were at a higher risk of in-hospital mortality (adjusted RR 1.56; 95%CI:1.13-2.15) than patients without stroke.
Conclusions In this multicenter cohort study, the cumulative incidence of acute ischemic stroke in hospitalized patients with COVID-19 was approximately 2%, with a higher risk in patients treated at an ICU. The majority of stroke patients had a poor outcome. The association between ischemic stroke and pulmonary embolism warrants further investigation.
Competing Interest Statement
Wouter M. Sluis is supported by the European Unions Horizon, 2020 research and innovation programme (grant no. 634809). Marijke Linschoten is supported by the Alexandre Suerman Stipend of the University Medical Center Utrecht. J.P. Kerklaan participates in the PACIFIC-stroke trial. Folkert W. Asselbergs is supported by University College London Hospitals National Institute for Health Research Biomedical Research and CardioVasculair Onderzoek Nederland 2015-12 eDETECT. M.J.H Wermer is supported by a personal grant from the Dutch Heart Foundation (Dr. Dekker Grant 2016T086), a personal VIDI grant from ZonMw/NWO (91717337) and a grant for the CORONIS project from ZonMW and the Dutch Heart Foundation. She served as a consultant to Biogen without payment. H.B. van der Worp served as a consultant to Bayer and LivaNova, with fees paid to his institution. Annemijn M. Algra is supported by a personal grant from the Dutch Heart Foundation (Dr. Dekker Grant 2016T023).
Funding Statement
CAPACITY-COVID is funded by the Dutch and British Heart Foundation, the EuroQol Research Foundation, Novartis Global, Amgen Europe, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
On the 17th of march 2020, the Medical Research Ethics Committee of the University Medical Center Utrecht, confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to the above mentioned study. (Reference number WAG/avd/20/010579) and has exempted it for further approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Twitter: @woutersluis; @annemijn_algra;
Data Availability
The data used for this study, including de-identified individual participant data and a data dictionary defining each field or variable within the dataset, can be made available upon reasonable request to the data access committee of CAPACITY-COVID. These data will be made available following publication of this work. A data sharing agreement must be signed before any data are shared.
Abbreviations
- COVID-19
- Coronavirus disease 2019
- ICU
- Intensive Care Unit
- PCR
- Polymerase chain reaction
- PE
- Pulmonary embolism
- AF
- Atrial fibrillation
- TIA
- Transient ischemic attack
- NIHSS
- National Institutes of Health Stroke Scale
- IVT
- Intravenous thrombolysis
- EVT
- Endovascular therapy
- TOAST
- Trial of Org 10172 in Acute Stroke Treatment
- mRS
- Modified Rankin scale
- IQR
- Interquartile range
- SD
- Standard deviation
- CI
- Confidence interval
- RR
- Risk ratio
